Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict.

Steinestel, Julie; Bernemann, Christof; Schrader, Andres J; Lennerz, Jochen K

Steinestel, Julie; Bernemann, Christof; Schrader, Andres J; Lennerz, Jochen K.

Affiliation

Steinestel J; Clinic of Urology, University Hospital Münster, Münster, Germany. Electronic address: julie.steinestel@ukmuenster.de.
Bernemann C; Clinic of Urology, University Hospital Münster, Münster, Germany.
Schrader AJ; Clinic of Urology, University Hospital Münster, Münster, Germany.
Lennerz JK; Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.

Eur Urol ; 71(1): 6-7, 2017 01.

Article in En | MEDLINE | ID: mdl-27641787

Subject(s)

Prostate-Specific Antigen; Prostatic Neoplasms; Humans; Male

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostate-Specific Antigen Limits: Humans / Male Language: En Journal: Eur Urol Year: 2017 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google